AbbVie Inc.
ABBV
株式のランク
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
株価
$285.11
最終同期: 2026-10-16
時価総額
$503.82B
変化（1日）
0.78%
変化（1年）
24.37%
国
US
取引 AbbVie Inc. (ABBV)
カテゴリー
Healthcare
AbbVie Inc.（ABBV）の配当履歴
AbbVie Inc.（証券コード：ABBV）は合計で39回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$45.62
配当利回り（TTM）：0.0287
すべての配当の合計（株式分割調整済み）は：$45.62
配当利回り（TTM）：0.0287
2016から2026までのAbbVie Inc.（ABBV）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 5.01% |
| 2022 | $5.64 | 8.42% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 4.96% |
| 2022 | $5.64 | 8.46% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 215.00% |
US
|
|
| 225.00% |
US
|
|
| 33.00% |
CH
|
|
| 223.00% |
US
|
|
| 29.00% |
CH
|
